Affordable Access

deepdyve-link
Publisher Website

Sphingolipidomics of drug resistant Candida auris clinical isolates reveal distinct sphingolipid species signatures

Authors
  • Kumar, Mohit1, 2
  • Singh, Ashutosh3
  • Kumari, Sonam2
  • Kumar, Praveen1
  • Wasi, Mohd.4
  • Mondal, Alok K.4
  • Rudramurthy, Shivaprakash M.5
  • Chakrabarti, Arunaloke5
  • Gaur, Naseem A.2
  • Gow, Neil A.R.6
  • Prasad, Rajendra1
  • 1 Amity Institute of Integrative Science and Health, and Amity Institute of Biotechnology, Amity University Gurgaon, Haryana, India
  • 2 Yeast Biofuel Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
  • 3 Department of Biochemistry, University of Lucknow, Lucknow, India
  • 4 School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
  • 5 The Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, India
  • 6 Medical Research Council Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK
Type
Published Article
Journal
Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids
Publisher
Elsevier
Publication Date
Jan 01, 2021
Volume
1866
Issue
1
Identifiers
DOI: 10.1016/j.bbalip.2020.158815
PMID: 32942047
PMCID: PMC7695621
Source
PubMed Central
Keywords
Disciplines
  • Article
License
Unknown

Abstract

• Candida auris isolates are susceptible to sphingolipid inhibitors myriocin and aureobasidin A. • The distribution of sphingolipid species is distinct among C. auris isolates resistant to different antifungals. • Phytoceramides are the most abundant class of sphingolipid. • Cer(d18:1/18:1) is the major of ceramide species in C. auris . • d19:2 glucosylceramide backbone is typically in abundance in AmB resistant C. auris isolates.

Report this publication

Statistics

Seen <100 times